Last reviewed · How we verify

NCT06953921

Correlation Between Serum Albumin Level and Severity of Hepatic Encephalopathy in Patients With Chronic Liver Disease in Sohag University Hospital

Recruiting now Last updated 1 May 2025
What this trial tests

trial in Hepatic Encephalopathy in 100 participants. Currently enrolling.

Timeline
12 March 2025
Primary endpoint
12 September 2025
12 September 2025

Quick facts

Lead sponsorSohag University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date12 March 2025
Primary completion12 September 2025
Estimated completion12 September 2025
Sites1 location across Egypt

Conditions studied

Sponsor

Sohag University

Who can join

18 and older, any sex, with Hepatic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

assess the correlation between serum albumin levels and the severity of hepatic encephalopathy in patients with chronic liver disease. assess the impact of albumin level on clinical course and outcomes of HE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatic Encephalopathy

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06953921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing